1-20 of 471
drug combinations
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Whole-Genome CRISPR Screen Reveals the Mechanism of Relapse in Patient-Derived Cells Representing High-Risk Paediatric ALL

Katarzyna Szoltysek, PhD, Helen Blair, Sirintra Nakjang, Ricky Tirtakusuma, Mankaran Singh, Ryan Nelson, Hesta McNeill, Catherine Dodd, Melanie Beckett, Lynsey McKenzie, Edward Law, Josef Vormoor, MD PhD, Deepali Pal, Olaf Heidenreich
Journal: Blood
Blood (2019) 134 (Supplement_1): 3952.
https://doi.org/10.1182/blood-2019-124818
Published: 2019
Journal Articles

The Combination of the BCL-2 Antagonist Venetoclax with the CD70-Targeting Antibody Cusatuzumab Synergistically Eliminates Primary Human Leukemia Stem Cells

Carsten Riether, PhD, Tanja Chiorazzo, PhD, Amy J. Johnson, PhD, Christina Diane Drenberg, PhD, Khaja Waheeduddin Syed, BPharm, MS, Mahan Moshir, MSc, Anna Hultberg, PhD, Nicolas Leupin, Hans De Haard, Adrian F Ochsenbein, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3918.
https://doi.org/10.1182/blood-2019-127464
Published: 2019
Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3965.
https://doi.org/10.1182/blood-2019-124392
Published: 2019
Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 3938.
https://doi.org/10.1182/blood-2019-124072
Published: 2019
Journal Articles

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Heinz Ahlert, MSc, BSc, Sanil Bhatia, PhD, Marc Remke, MD, Melf Sönnichsen, M.Sc., Niklas Dienstbier, M.Sc., Ute Fischer, PhD, Julia Hauer, MD, Arndt Borkhardt, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3883.
https://doi.org/10.1182/blood-2019-128136
Published: 2019
Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4404.
https://doi.org/10.1182/blood-2019-121937
Published: 2019
Journal Articles

PI3Kδ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy

Jessica A.O. Zimmerman, MD, Mimi Fang, Arunkumar Modi, MBBS, MPH, Adam Dupuy, PhD, Sarah K. Tasian, MD, Miles A. Pufall, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2572.
https://doi.org/10.1182/blood-2019-129205
Published: 2019
Journal Articles

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

Laury Poulain, PhD, Adrien Grenier, MD PhD, Johanna Mondesir, MD, Arnaud Jacquel, PhD, Claudie Bosc, Lucille Stuani, PhD, Rudy Birsen, MD, Sarah Mouche, Justine Decroocq, MD, Fetta Mazed, PhD, Benoit Viollet, PhD, Patrick Auberger, PhD, Pierre Sujobert, MD PhD, Didier Bouscary, MD PhD, Jean-Emmanuel Sarry, PhD, Jerome Tamburini, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2552.
https://doi.org/10.1182/blood-2019-123364
Published: 2019
Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2574.
https://doi.org/10.1182/blood-2019-123287
Published: 2019
Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2550.
https://doi.org/10.1182/blood-2019-128626
Published: 2019
Journal Articles

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2528.
https://doi.org/10.1182/blood-2019-123338
Published: 2019
Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2564.
https://doi.org/10.1182/blood-2019-131635
Published: 2019
Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Mohammad Hojjat-Farsangi, MSc,PhD, Amineh Ghaderi, MSc, AmirHossein Daneshmanesh, MD PhD, Jemina Lehto, MSc, Ali Moshfegh, MSc,PhD, Parviz Kokhaei, MSc,PhD, Jan Vågberg, MSc,PhD, Elisabeth Olsson, MSc,PhD, Charlotta Löfberg, MSc,PhD, Charlotta Carina Norström, MSc,PhD, Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD Prof.
Journal: Blood
Blood (2019) 134 (Supplement_1): 2565.
https://doi.org/10.1182/blood-2019-126801
Published: 2019
Journal Articles

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

Joseph M Brandwein, MD, Asmaa Basonbul, MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 2646.
https://doi.org/10.1182/blood-2019-129529
Published: 2019
Journal Articles

Quantitative Proteomic Analysis of Relapsed Multiple Myeloma Identifies CDK6 Upregulation As a Potential Targetable Resistance Mechanism for Lenalidomide

Yuen Lam Dora Ng, Stephan Bohl, Evelyn Ramberger, Oliver Popp, Imke Bauhuf, Anna Dolnik, Christian Steinebach, Michael Gütschow, Lars Bullinger, Philipp Mertins, Jan Kroenke
Journal: Blood
Blood (2019) 134 (Supplement_1): 2567.
https://doi.org/10.1182/blood-2019-130682
Published: 2019
Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 2628.
https://doi.org/10.1182/blood-2019-129198
Published: 2019
Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2963.
https://doi.org/10.1182/blood-2019-126189
Published: 2019
Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3052.
https://doi.org/10.1182/blood-2019-130807
Published: 2019
Journal Articles

Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition

Nadine Abdallah, MD, S. Vincent Rajkumar, MD, Dragan Jevremovic, MD PhD, Prashant Kapoor, MD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Martha Q. Lacy, MD, Francis K. Buadi, MB, CHB, Suzanne R. Hayman, MD, David Dingli, MD PhD, Eli Muchtar, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, Mustaqeem A. Siddiqui, MDMBA, Ronald S. Go, MD, Nelson Leung, MD, Yi L. Hwa, APRN, CNP, DNP, Miriam A. Hobbs, APRN, CNP, DNP, Amie Fonder, PA-C, MS, Robert A. Kyle, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3080.
https://doi.org/10.1182/blood-2019-131835
Published: 2019
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
https://doi.org/10.1182/blood-2019-125939
Published: 2019